Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis.

@article{Radstake2007MacrophageMI,
  title={Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis.},
  author={Timothy R D J Radstake and Jaap Fransen and Erik J. M. Toonen and Marieke J. H. Coenen and Agnes E Eijsbouts and Rachelle P. Donn and Frank H. J. van den Hoogen and Piet L. C. M. van Riel},
  journal={Annals of the rheumatic diseases},
  year={2007},
  volume={66 11},
  pages={1525-30}
}
BACKGROUND Macrophage migration inhibitory factor (MIF) is an inflammatory mediator associated with RA severity. In various diseases, MIF polymorphisms are associated with clinical response glucocorticoid (GC) treatment. It is unclear whether MIF polymorphisms determine GC response in rheumatoid arthritis (RA) and to other RA treatments. Therefore, the… CONTINUE READING